Business Wire

GALDERMA

Share
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a single dose of Dysport ® (abobotulinumtoxinA) for Injection (50U, 75U, 100U or 125U) versus placebo for the treatment of moderate to severe frown lines between the eyebrows (glabellar lines). Results showed that the study met its primary endpoint, with significantly more subjects treated with Dysport ® at all four doses achieving a composite two grade improvement responder rate than those treated with placebo at one month. Data from secondary endpoints demonstrated promising results for a potential prolonged duration of effect correlated with higher doses. Dysport ® , also marketed as Azzalure® in some countries, is a prescription injection for temporary improvement in the look of moderate to severe glabellar lines in adults less than 65 years of age.

“We are encouraged that these study results demonstrate that a single dose of Dysport ® has a rapid onset, long-lasting effect and is well tolerated,” said John H. Joseph, M.D., investigator for the study and director of The Clinical Testing Center of Beverly Hills. “At all doses tested in the trial, Dysport ® had a strong safety profile, including very few cases of eyelid ptosis.”

Phase 2 Dose-Escalating Study Design and Results
The multicenter, randomized, dose-ranging, double-blind, placebo-controlled Phase 2 study enrolled 401 subjects ages 18 to 65 with moderate to severe glabellar lines at maximum frown. Study participants were randomized 4:1 to receive a single dose of Dysport ® (50U, the dose in the FDA-approved label, 75U, 100U or 125U) or placebo and followed for nine months. The primary objective of the study was to evaluate the efficacy of a single dose of Dysport ® as assessed by the composite responder rate at maximum frown at one month. Secondary objectives evaluated other measures of efficacy as well as duration of treatment response, subject satisfaction, aesthetic improvement and onset of treatment response.

Top-line efficacy results showed that the study met its primary endpoint. After one month, all dose groups treated with Dysport ® showed a statistically significant composite (investigator and subject-assessed) ≥2-grade improvement when compared with placebo. Favorable results were achieved for all doses in the secondary objectives, including a ≥1-grade improvement and subject satisfaction throughout the study duration. Dysport ® was well tolerated with a similar safety profile across all doses tested. Treatment-related adverse events were mild or moderate in severity and transient, and no treatment-related serious adverse events were reported.

“This phase 2 study underscores our commitment to bring efficacious products and long-lasting results to customers,” said Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma. “Based on these encouraging safety and long-term efficacy results, as well as continued patient satisfaction, we are evaluating future clinical studies.”

About Galderma's collaboration with Ipsen
Dysport ® (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. Dysport is also marketed as Azzalure® in the EU for the treatment of glabellar lines with more than 40 million treatments in the EU and U.S. combined and with approvals in 74 countries.

Dysport ® is manufactured by Ipsen, a global specialty-driven pharmaceutical company. Since 2009, Galderma and Ipsen have had a strategic partnership under which Galderma has promoted and distributed Ipsen's botulinum toxin type A products in aesthetic indications. The Ipsen-Galderma strategic partnership now covers China, the United States, the European Union, Australia, South Korea, Canada, Brazil, Argentina, and certain other countries. Ipsen continues to promote Dysport ® within certain therapeutic indications in countries around the world.
For more information on Ipsen, visit www.ipsen.com .

About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetic solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com/ .

# # #

Visit www.fda.gov/medwatch or call 1‐800‐FDA‐1088.

For U.S. audiences please see Dysport Full Prescribing Information including Medication Guide at DysportUSA.com .

The Dysport trademark is used under license. All trademarks are the property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

I-Pulse Welcomes Codelco as Strategic Investor13.10.2025 07:00:00 CEST | Press release

World’s Largest Copper Producer Joins Mining Majors Backing I-Pulse TechnologyI-Pulse Employs High Pulsed Power to Create Disruptive Solutions for Resource Discovery, Mining, Manufacturing, Agriculture and Geothermal Energy I-Pulse Co-Founder, Chairman and CEO Robert Friedland and Laurent Frescaline, Co-Founder and Chief Technology Officer, are pleased to welcome Codelco as the company’s latest strategic investor and key partner in the development and commercialization of its disruptive pulsed power technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251012216264/en/ I-Pulse Co-Founder Chairman and CEO Robert Friedland and Codelco Chairman Máximo Pacheco Codelco, the world’s largest copper miner, will provide capital and real-world experience to accelerate the commercialization of I-Pulse’s breakthrough innovations for drilling, continuous underground mining, tunnelling and rock crushing. Codelco joins world leading

AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 202513.10.2025 01:31:00 CEST | Press release

Results from the Phase 1b dose escalation of the TheraPb Phase 1/2 trial are the first clinical data for a Lead-212 (212Pb)-based-PSMA radioligand therapy The abstract presents a favorable safety profile for 212Pb-ADVC001 and promising anti-tumor activity, underscoring its potential to enhance therapeutic options for patients with metastatic prostate cancer The upcoming presentation at ESMO will feature updated safety and efficacy results from all seven Phase 1b treatment cohorts AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, announces a presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany, from October 17-21, 2025. The presentation will feature promising results from the Phase 1b dose escalation of the Phase 1/2 TheraPb study, evaluating ADVC001, a Lead-212-based PSMA-targeted alpha therapy, in metastatic castration-resistant prostate cancer (mCRPC). This will be t

Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 202513.10.2025 00:05:00 CEST | Press release

Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. “We are encouraged by the positive findings being presented with our TGFβR2×PD-1 and KRAS G12D inhibitor programs, which validate our rationale for advancing the development of these novel investigational compounds," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "There remains a significant need for new treatment options for patients with advanced solid tumors like colorectal cancer and pancreatic ductal adenocarcinoma and we look forward to providing updates on these clinical development programs.” Details on INCA33890 and INCB161734 oral presentations at ESMO include: INCA33890 (PD-1/TGFβR

Day Two of the 11th World FZO Congress Highlights the Role of Digitization and Sustainability in Shaping the Future of Free Zones11.10.2025 16:52:00 CEST | Press release

The World Free Zones Organization’s 11th annual World Congress continued its agenda today with a focus on the role of digitization and sustainability in the future of free zones and the mechanisms for enhancing their position as strategic trade gateways. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251011933300/en/ Dr Al Zarooni and President of CIRD launching the global institute (Photo: AETOSWire) The day’s sessions featured a series of sessions addressing critical themes such as the digitization of trade corridors, the impact of the OECD Global Minimum Tax, and the role of free zones as regional trade gateways. Sustainability took centre stage with sessions focusing on the transition to net-zero through renewable energy, circular economy models, and green financing frameworks. Speakers underscored that decarbonization is not only a climate imperative but also a competitive advantage for the next generation of free zones

IonQ to Participate in ComoLake2025, Advancing Quantum Collaboration in Italy10.10.2025 22:05:00 CEST | Press release

IonQ CEO to discuss how quantum accelerates innovation and economic growth at Italy’s leading tech and policy forum IonQ (NYSE: IONQ), a leading quantum company, today announced its participation in the ComoLake2025 Digital Innovation Forum, one of Italy’s most prominent technology events focused on digital transformation, infrastructure, and innovation policy. At ComoLake2025, taking place October 14–17 at the Villa Erba International Exhibition and Congress Center in Cernobbio, Niccolò de Masi, Chairman and CEO at IonQ, will deliver a special address, offering strategic insights into how quantum computing is reshaping infrastructure, industry, and Europe’s digital leadership. Marco Pistoia, Senior Vice President of Industry Relations at IonQ, will participate in the round table “Pan-European Quantum Industry Forum - Dialogue between Industry, Politics, and Research for Europe's Quantum Leadership” focused on strengthening Europe’s position in the global quantum landscape. Organized b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye